BCMA-targeted immunotherapy for multiple myeloma

B cell maturation antigen (BCMA) is a novel treatment target for multiple myeloma (MM) due to its highly selective expression in malignant plasma cells (PCs). Multiple BCMA-targeted therapeutics, including antibody-drug conjugates (ADC), chimeric antigen receptor (CAR)-T cells, and bispecific T cell...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Bo, Jiang, Tianbo, Liu, Delong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7499842/
https://www.ncbi.nlm.nih.gov/pubmed/32943087
http://dx.doi.org/10.1186/s13045-020-00962-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7499842/
https://www.ncbi.nlm.nih.gov/pubmed/32943087
http://dx.doi.org/10.1186/s13045-020-00962-7

Ejemplares similares